US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Geneoscopy, Inc.

News headline image
CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy's ColoSense® Test Included as a Preferred Option in the American Cancer Society Colorectal Cancer Screening Guidelines Update
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy’s Scrape-Free Collection Method for Colorectal Cancer Screening Validated by New Data and Peer-Reviewed Publication
From Geneoscopy, Inc.
Via Business Wire
News headline image
Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy to Participate in Upcoming Investor Conferences
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences’ ’781 Patent
From Geneoscopy, Inc.
Via Business Wire
News headline image
Modeling Study Published in Clinical Gastroenterology and Hepatology Validates Geneoscopy’s ColoSense® Real-World Screening Impact
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy’s RNA-Based ColoSense Test Included in Latest National Comprehensive Cancer Network (NCCN) Guidelines
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Sibling Co-founders Named Finalists for EY Entrepreneur Of The Year 2025 Heartland Award
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Appoints Amit Bhalla as Chief Financial Officer to Advance Strategic Growth and Support Commercialization Efforts
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy’s Dr. Erica Barnell to Speak at ACG’s ‘Leading With Guts’ Course on Expanding Career Opportunities in Gastroenterology
From Geneoscopy, Inc.
Via Business Wire
News headline image
U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy’s Petition Challenging Validity of a Second Patent Asserted by Exact Sciences
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
From Geneoscopy, Inc.
Via Business Wire
Tickers BIO
News headline image
Geneoscopy’s Dr. Erica Barnell to Present at Women @ Work Summit and American Gastroenterological Association Workshop
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Receives New York State Department of Health Permit, Expanding Ability to Provide Laboratory Services Nationwide
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy to Present at Gastroenterology and Cancer Surveillance Conferences, Highlighting Advancements in Colorectal Cancer Screening and Early Detection
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy’s CEO Andrew Barnell to Present at Upcoming Investor Conferences
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy’s Novel Stool-Based RNA Platform Shows High Accuracy in Monitoring Crohn’s Disease
From Geneoscopy, Inc.
Via Business Wire
News headline image
U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy’s Petition Challenging Validity of ‘781 Patent Owned by Exact Sciences
From Geneoscopy, Inc.
Via Business Wire
News headline image
Peer-Reviewed Study Confirms Reliability of ColoSense, Geneoscopy’s Noninvasive Multi-target Stool RNA Colorectal Cancer Screening Test
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Files Counterclaims Against Exact Sciences
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Advances Mission to Transform Gastrointestinal Health at Digestive Disease Week 2024
From Geneoscopy, Inc.
Via Business Wire
News headline image
Court Dismisses Exact Sciences’ ‘781 Patent Infringement Claim Against Geneoscopy
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Expands Leadership Team to Support ColoSense™ Rollout and Advance Precision IBD Solutions
From Geneoscopy, Inc.
Via Business Wire
News headline image
FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)
From Geneoscopy, Inc.
Via Business Wire
News headline image
Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent
From Geneoscopy, Inc.
Via Business Wire